share_log

Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22

Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22

武田製藥21財年核心利潤增長1%，預計22財年增長勢頭
Benzinga Real-time News ·  2022/05/11 06:34
  • Takeda Pharmaceutical Company Limited (NYSE:TAK) reported a fiscal 2021 core net profit of ¥663.7 billion, an increase of 1.3% from the prior year. Core earnings per share reached ¥425, up 1.2%.
  • FY21 net profit declined 38.8% to ¥230.1 billion.
  • Fiscal 2021 core revenue was ¥3.42 trillion, an underlying increase of 7.4%.
  • Gastroenterology sales reached ¥875.7 billion, up 7% on an underlying basis driven by gut-selective Entyvio and anti-acid therapy Takecab. Takeda is no longer expecting entry of biosimilars upon loss of data exclusivity.
  • Also See: Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients.
  • Rare Diseases sales decreased 1% to ¥611.2 billion in reported revenue, impacted by a decline in line with expectations in Rare Hematology due to intensified competition. 
  • Plasma Derived Therapy Immunology segment revenues increased 14% to ¥507.0 billion, and Oncology sales grew 8% to ¥468.7 billion.
  • Neuroscience sales were up 10% to ¥482.3 billion.
  • Guidance: Takeda forecasts FY22 core sales of ¥3.69 trillion, up 7.9%.
  • In FY2022, Takeda expects continued revenue growth. Core operating profit is expected to reach ¥1.1 trillion, mainly driven by business momentum.
  • Price Action: TAK shares closed 1.33% higher at $14.52 on Tuesday.
  • 武田藥品株式會社(紐約證券交易所股票代碼：TAK)公佈2021財年核心淨利潤為人民幣6637億元，同比增長1.3%。每股核心收益達到425元，增長1.2%。
  • 2011財年淨利潤下降38.8%，至人民幣2301億元。
  • 2021財年核心收入3.42萬億元，潛在增長7.4%。
  • 胃腸科銷售額達到8,757億元，在腸道選擇性Entyvio和抗酸療法Takecab的推動下，基本銷售額增長7%。武田不再期待在失去數據排他性後進入生物仿製藥。
  • 另請參閲： 武田公司的Maribavir降低了移植後感染患者的住院率和住院時間.
  • 罕見疾病銷售額下降1%，至人民幣6,112億元，受競爭加劇導致罕見血液病銷售額下降符合預期的影響。
  • 血漿衍生療法免疫部門的收入增長了14%，達到人民幣5070億元，腫瘤學的銷售額增長了8%，達到人民幣4687億元。
  • 神經科學的銷售額增長了10%，達到人民幣4823億元。
  • 指導意見：武田預計，2012財年核心銷售額為人民幣3.69萬億元，增長7.9%。
  • 武田預計，在2022財年，收入將繼續增長。預計核心營業利潤將達到1.1萬億元，主要受業務動能推動。
  • 價格行動：德意志銀行股價週二收高1.33%，報14.52美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論